Jiajun Li

Jiajun Li

Auto-generated profile, based on publicly available information

Jiajun Li

Institute of Physical Chemistry, Department of Chemistry, University of Basel, 4058 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
XJXinjian Ji
Xinjian Ji
LFLluc Farrera-Soler
Lluc Farrera-Soler
JLJiajun Li
Jiajun Li
GSGontran Sangouard
Gontran Sangouard
NSNathan De Sadeleer
Nathan De Sadeleer
CHChristian Heinis
Christian Heinis
Small, nonpolar cyclic peptides can both bind challenging targets and cross cell membranes, making them attractive for addressing currently undruggable targets such as many protein–protein interactions (PPIs). However, developing such compounds de novo without prior information about lead structures such as natural ligands or fragments remains a notable challenge. Here we show that functional screening of structurally highly diverse cyclic peptide libraries synthesized at nanomole scale allows identification of sub-kDa inhibitors of a PPI. By screening 15,360 fully random cyclic peptides, we were able to identify an inhibitor of the E3 ligase adaptor Keap1 and its substrate Nrf2. Optimization by rapid design–build–test cycles produced a membrane-permeable compound active in live cells. This study demonstrates that large, diverse cyclic peptide libraries can enable the discovery of cell-permeable PPI inhibitors from the ground up, providing a way to harness the powerful modality of small cyclic peptides to address often difficult-to-target intracellular interactions. The alternative text for this image may have been generated using AI.

9 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PVPratik Vyas
Pratik Vyas
JLJiajun Li
Jiajun Li
RVRosario Vanella
Rosario Vanella
MNMichael A. Nash
Michael A. Nash
Candida auris ( C. auris ) is a rapidly emerging, multidrug-resistant fungal pathogen whose persistence is partly driven by adhesion to host tissues and abiotic surfaces. Surface-colonization factor 1 (Scf1) is a C. auris -specific adhesin implicated in surface adhesion, biofilm formation, virulence, and persistence in health care settings. However, the human proteins recognized by Scf1 and the response of these interactions to hydrodynamic flow and shear stress were previously unknown. Using yeast surface display, spinning-disk adhesion and FACS-based binding assays, we show that the N-terminal adhesive domain of Scf1 binds the cell-surface glycoprotein mucin-1 (MUC1) and the extracellular matrix proteins vitronectin (VIT) and fibronectin (FN), while exhibiting no detectable binding to collagen I, collagen IV, or fibrinogen. Hydrodynamic shear stress was found to tune ligand preference, with VIT being preferred at equilibrium and MUC1 being the more strongly bound target under flow. Epitope mapping by deep mutational scanning (DMS) of Scf1 against MUC1, VIT and FN identified shared binding patches consisting of predominantly cationic and aromatic residues involved in recognizing all three ligands. Mutations within these regions reduced binding without compromising yeast display expression levels, indicating that these residues are involved in ligand recognition and that mutations at these positions do not compromise global protein folding stability. These findings establish the Scf1 N-terminal domain as a semi-promiscuous ligand-recognition domain for a structurally diverse set of human proteins and suggest that a mechanosensitive adhesion mechanism contributes to C. auris colonization.

21 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BYByeongseon Yang
Byeongseon Yang
DGDiego E. B. Gomes
Diego E. B. Gomes
ZLZhaowei Liu
Zhaowei Liu
MSMariana Sá Santos
Mariana Sá Santos
JLJiajun Li
Jiajun Li
MNMichael A. Nash
Michael A. Nash
Protein-protein complexes can vary in mechanical stability depending on the direction from which force is applied. Here we investigated the anisotropic mechanical stability of a molecular complex between a therapeutic non-immunoglobulin scaffold called Affibody and the extracellular domain of the immune checkpoint protein PD-L1. We used a combination of single-molecule AFM force spectroscopy (AFM-SMFS) with bioorthogonal clickable peptide handles, shear stress bead adhesion assays, molecular modeling, and steered molecular dynamics (SMD) simulations to understand the pulling point dependency of mechanostability of the Affibody:(PD-L1) complex. We observed diverse mechanical responses depending on the anchor point. For example, pulling from residue #22 on Affibody generated an intermediate unfolding event attributed to partial unfolding of PD-L1, while pulling from Affibody’s N-terminus generated force-activated catch bond behavior. We found that pulling from residue #22 or #47 on Affibody generated the highest rupture forces, with the complex breaking at up to ∼ 190 pN under loading rates of ∼10 4 -10 5 pN/sec, representing a ∼4-fold increase in mechanostability as compared with low force N-terminal pulling. SMD simulations provided consistent tendencies in rupture forces, and through visualization of force propagation networks provided mechanistic insights. These results demonstrate how mechanostability of therapeutic protein-protein interfaces can be controlled by informed selection of anchor points within molecules, with implications for optimal bioconjugation strategies in drug delivery vehicles.

17 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYang Sun
Yang Sun
JLJiajun Li
Jiajun Li
RVRosario Vanella
Rosario Vanella
HLHaipei Liu
Haipei Liu
ZLZhaowei Liu
Zhaowei Liu
MNMichael A. Nash
Michael A. Nash
Achieving high binding strength and efficient delivery of molecular cargo to tumor cells is a significant challenge in cancer immunotherapy. Current research has focused on obtaining antibodies that bind their targets with high affinity (i.e. low equilibrium dissociation constant, KD). However, such an approach neglects the influence of hydrodynamic fluid flow along the surfaces of cells and tissues, which can impart mechanical stress and lead to rapid unbinding of antibodies under flow. Here, we investigated how altering the anchor point within a non-antibody binding scaffold called Anticalin can enhance particle adhesion to the immune checkpoint CTLA-4 on human cells experiencing hydrodynamic shear. By introducing bioorthogonal clickable amino acids into Anticalin at various positions, we investigated the influence of different unbinding geometries on the stability of the Anticalin:(CTLA-4) complex. Both single-molecule AFM and quantitative bead-based adhesion assays on CTLA-4+ human cells demonstrate how optimal choice of the anchor point can stabilize the complex and enhance the adhesion strength of receptor-targeted particles. These results demonstrate how anchor point engineering can enhance particle adhesion and delivery to immunotherapy targets.